Jerome Bettis' Touchdown Pass Named 'Levitra(R) (vardenafil HCI) Play of the Year'

Jerome Bettis' Touchdown Pass Named 'Levitra(R) (vardenafil HCI) Play of the Year'

10-Yard Halfback Toss Named Season's Best by Fans

JACKSONVILLE, Fla., Feb. 2 /PRNewswire/ -- Today, Pittsburgh Steelers running back Jerome Bettis' 10-yard touchdown pass to tight end Jerame Tuman in Week 14 against the New York Jets has been voted the "LEVITRA(R) (vardenafil HCI) PLAY OF THE YEAR."

Bettis' touchdown pass edged out Philadelphia Eagles quarterback Donovan McNabb's scrambling 60-yard pass to wide receiver Freddie Mitchell in Week 10 against the Dallas Cowboys; Green Bay Packers running back Ahman Green's 90- yard touchdown run in Week 7 against the Dallas Cowboys; Dallas Cowboys running back Julius Jones' game-winning, 17-yard touchdown run in Week 13 against the Seattle Seahawks; and Baltimore Ravens safety Ed Reed's NFL record-breaking, 106-yard interception return for a touchdown in Week 9 against the Cleveland Browns.

With the Steelers and Jets deadlocked at 3-3 early in the fourth quarter, Bettis took a handoff and ran right before stopping and lofting a pass to tight end Jerame Tuman in the endzone. Bettis, who has three career touchdown passes, also ran for a touchdown on the next drive as the Steelers locked up the AFC North title with a 17-6 victory over the Jets. Bettis, who ran for 57 yards on the day, surpassed the 13,000-yard mark for his career.

NFL Hall of Famers, Coach Mike Ditka and Tony Dorsett, spokespersons for the NFL's "Tackling Men's Health" program awarded Bettis with the "LEVITRA(R) PLAY OF THE YEAR" trophy at a ceremony in Jacksonville.

The "LEVITRA(R) PLAY OF THE YEAR" award was created by the NFL to recognize the single most exciting play of the year as determined by the fans through voting on http://www.nfl.com/. Bettis' play qualified for the "LEVITRA(R) PLAY OF THE YEAR" after it was voted the Week 14 "LEVITRA(R) PLAY OF THE WEEK."

For details and video of this year's nominees, winners and finalists visit http://www.nfl.com/.

Levitra, a treatment for erectile dysfunction developed by Bayer Healthcare and GlaxoSmithKline (GSK), is jointly promoted in the U.S. by GSK and Schering-Plough Corporation.

2004 LEVITRA(R) PLAY OF THE WEEK Winners

Week Player Play Description

1 Donovan McNabb, Philadelphia Three-yard TD pass to Terrell Owens
against the Giants

2 Roy Williams, Detroit 14-yard TD reception from
Joey Harrington against the Texans

3 Joe Horn, New Orleans Nine-yard TD reception from
Aaron Brooks against the Rams

4 Troy Polamalu, Pittsburgh 26-yard interception return for a
touchdown against the Bengals

5 Brandon Lloyd, San Francisco 23-yard TD reception from
Tim Rattay against the Cardinals

6 Kimo von Oelhoffen, 21-yard fumble recovery against the
Pittsburgh Cowboys

7 Ahman Green, Green Bay 90-yard touchdown run against the
Cowboys

8 Plaxico Burress, Pittsburgh Four-yard touchdown reception from
Ben Roethlisberger against the
Patriots

9 Ed Reed, Baltimore 106-yard interception return for a
touchdown against the Browns

10 Donovan McNabb, Philadelphia 60-yard scrambling pass against the
Cowboys

11 Chad Johnson, Cincinnati 36-yard touchdown reception from
Carson Palmer against the Steelers

12 Ronald Curry, Oakland One-handed, six-yard touchdown
reception from Kerry Collins
against the Broncos

13 Julius Jones, Dallas Game-winning, 17-yard touchdown run
against the Seahawks

14 Jerome Bettis, Pittsburgh 10-yard touchdown pass to
Jerame Tuman against the Jets

15 Darren Sharper, Green Bay 15-yard fumble return for a
touchdown against the Jaguars

16 Chad Johnson, Bengals Game-winning, four-yard touchdown
reception from Jon Kitna against
the Giants

17 James Harrison, Pittsburgh 18-yard fumble recovery and return
for a touchdown against the Bills

About LEVITRA


LEVITRA is a prescription medicine that is used to treat erectile dysfunction (ED). Men taking nitrate drugs, often used to control chest pain (also known as angina), should not take LEVITRA. Men who use alpha blockers, sometimes prescribed for high blood pressure or prostate problems, also should not take LEVITRA. Such combinations could cause blood pressure to drop to an unsafe level.

You should not take LEVITRA if your doctor determines that sexual activity poses a health risk for you. Men who experience an erection for more than four hours should seek immediate medical attention. LEVITRA does not protect against sexually transmitted diseases.

The starting dose of LEVITRA is 10 mg taken no more than once per day. Your doctor will decide the dose that is right for you. In patients taking certain medications such as ritonavir, indinavir, ketoconazole, itraconazole, and erythromycin, lower doses of LEVITRA are recommended, and time between doses of LEVITRA may need to be extended.

In clinical trials, the most commonly reported side effects were headache, flushing, and stuffy or runny nose. LEVITRA is available in 2.5-mg, 5-mg, 10-mg, and 20-mg tablets.

About Erectile Dysfunction

The consistent or recurrent inability of a man to attain and/or maintain a penile erection sufficient for sexual performance(1) -- is a common health condition among men that is largely untreated. It is estimated that some degree of ED affects more than one half of all men over the age of 40(2) - 152 million men worldwide(3) and 30 million men in the United States alone.(4) Despite the high prevalence of sexual problems, nine out of 10 men in the U.S. have not yet sought treatment from a physician.(5)

1. Jardin A, Wagner G, Khoury S, et al. Recommendations of the 1st International Consultation on Erectile Dysfunction. Co-sponsored by the World Health Organization (WHO), International Consultation on Urological Diseases (ICUD) and Societe Internationale d'Urologie (SIU) and held July 1-3, 1999, Paris. 2000, p. 713.

2. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.

3. Aytac IA, McKinlay JB, Krane RI. The likely worldwide increase of erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 1999;84:50-56

4. National Institutes of Health, Consensus Development Conference Statement, December 7-9, 1992. Online data: http://odp.od.nih.gov/consensus/cons/091/091_statement.htm. (accessed 8/26/02).

5. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-544.

About GSK

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

About Schering-Plough

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its more than 30,000 people around the world. For information, visit http://www.schering-plough.com/.

For more information about LEVITRA, please visit http://www.levitra.com/.

Contact: Contact:
Seth Rubin Matt Hill
Alan Taylor Communications National Football League
212-714-1280 x353 904-391-4262
seth@alantaylor.comhillm@nfl.com


Source: GSK; Schering-Plough

CONTACT: Seth Rubin of Alan Taylor Communications, +1-212-714-1280 x353,
seth@alantaylor.com for GSK and Schering-Plough; or Matt Hill of National
Football League, +1-904-391-4262, hillm@nfl.com

Web site: http://www.nfl.com/
http://www.levitra.com/
http://www.schering-plough.com/


-------
Profile: intent